Lee Arnold
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Drugs. 2025 May;85(5):695-698. doi: 10.1007/s40265-025-02164-2. Epub 2025 Apr 1.
Cosibelimab (UNLOXCYT; cosibelimab-ipdl) is an anti-PD-L1 antibody developed by Checkpoint Therapeutics for the treatment of advanced cancers, including metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC). Cosibelimab is the first approved anti-PD-L1 therapy in the USA for the treatment of adults with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation. In contrast to other anti-PD-L1 antibodies, cosibelimab can induce antibody-dependent cell mediated cytotoxicity as it includes a functional F domain. This article summarizes the milestones in the development of cosibelimab leading to this first approval for this indication.
科西贝利单抗（UNLOXCYT；cosibelimab-ipdl）是Checkpoint Therapeutics公司研发的一种抗程序性死亡配体1（PD-L1）抗体，用于治疗晚期癌症，包括转移性或局部晚期皮肤鳞状细胞癌（mCSCC或laCSCC）。科西贝利单抗是美国首个获批用于治疗不适合进行根治性手术或根治性放疗的成年mCSCC或laCSCC患者的抗PD-L1疗法。与其他抗PD-L1抗体不同，科西贝利单抗可诱导抗体依赖性细胞介导的细胞毒性，因为它包含一个功能性F结构域。本文总结了科西贝利单抗在该适应症首次获批之前的研发历程中的重要节点。
